
Kontigo Care Q4 2022 - Good conclusion to 2022

Redeye provides an update on Kontigo Care following its Q4 2022 report. We saw a positive end to 2022, with growth in active licenses returning in the fourth quarter. We reiterate our base case of SEK11per share, while we revise our short-term projections in light of a weaker Swedish municipal economy in 2023.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Kontigo Care Q4 2022 - Good conclusion to 2022